Manufacturing Supply. A description of the anticipated source of supply of Compound Product used in the clinical trials shall be set forth in the Development Plan.
Manufacturing Supply. 63 9. INVENTIONS........................................................................64 10.
Manufacturing Supply. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance with applicable law and with good manufacturing practices. Since [***], neither the Company nor any Affiliate of the Company has experienced any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. The Company has on hand or has made adequate provisions to secure sufficient clinical quantities of Products to complete all clinical trials and all activities required for Marketing Approvals, in each case, that are ongoing or planned as of the date hereof. The Company has on hand or has made adequate provisions to secure sufficient quantities of Jelmyto to support the commercial launch of Jelmyto in the Territory.
Manufacturing Supply. 7.1 Silence Obligations. Silence, through one or more Third Party contract manufacturers, shall be responsible for all manufacturing activities necessary to perform any activities contemplated by a Work Plan, at, subject to Section 5.4.2, its own expense.
7.2 Cooperation and Technology Transfer.
Manufacturing Supply. Subject to Clause 16, Anesta shall by itself or through its Affiliates, Anesta Sub-Licensees or permitted sub-contractors under Clause 14.3 manufacture Finished Goods for sale by Anesta, its Affiliates, Anesta Sub-Licensees and co-promoters (as defined in Clause 3.4) in all countries of the Territory. To the extent requested by Anesta, ImmuPharma shall use Commercially Reasonable Efforts to facilitate Anesta’s efforts to obtain supply of the Licensed Molecules or Licensed Product from ImmuPharma’s current supplier.
Manufacturing Supply. 8.1 Silence Manufacturing During Research Plan. Silence, through one or more Third Party contract manufacturers, shall be responsible for all Manufacturing activities necessary to perform any of its obligations under a Research Plan.
Manufacturing Supply. JT shall be responsible for all obligations relating to the manufacture of [*] Vaccine in Japan. In the event that JT wishes to purchase [*] Vaccine from Corixa, JT shall notify Corixa in a written request for proposal ("RFP") and shall set forth the types and amounts of [*] Vaccine that JT desires to obtain. Thereupon, Corixa shall respond to the RFP within [*] from receipt of the RFP. If Corixa currently manufactures the [*] Vaccine and JT wishes that Corixa be its supplier of [*] Vaccine for Japan, JT and Corixa shall negotiate in good faith a manufacturing and supply agreement therefor, the terms of which shall be substantially consistent with other Corixa manufacturing and supply agreements in comparable circumstances entered into no more than [*] of the date of JT's RFP (or which will otherwise be commercially reasonable if there are no such comparable agreements). If Corixa is not the manufacturer for the [*] Vaccine and JT wishes that Corixa be its supplier of [*] Vaccine for Japan, Corixa may at its option either supply [*] Vaccine to JT itself on terms to be agreed by the parties, arrange for the supply to JT by a Third Party or license to JT all of Corixa's manufacturing know-how and other technologies including patents and patent applications necessary or useful for and directly related to the manufacture of the [*] Vaccine, in each case on terms to be negotiated by the parties in good faith.
Manufacturing Supply. 6 5.1. Exclusivity..................................... 6 5.1.1. Failure to perform....................... 6 5.2. TKJ Inc. Contribution........................... 6
Manufacturing Supply. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance with applicable law and with good manufacturing practices. Since [***], neither the Parent nor any Affiliate of the Parent has experienced any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. The Seller has on hand or has made adequate provisions to secure sufficient clinical quantities of Products to complete all clinical trials and all activities required for Marketing Approvals, in each case, that are ongoing or planned as of the Effective Date. The Seller has on hand or has made adequate provisions to secure sufficient quantities of LUMRYZ to support the commercial launch of LUMRYZ in the Territory.
Manufacturing Supply. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance with applicable law and with good manufacturing practices. Since [***], neither the Seller nor any of its Affiliates has experienced any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. The Seller has on hand or has made plans for adequate provisions to secure sufficient clinical quantities of Products to complete all Clinical Trials and all activities required for Marketing Approvals, in each case, that are ongoing or planned as of the date hereof.
